Home › BioCryst Pharmaceuticals Rating Lowered to Neutral at Zacks
 

Keywords :   


BioCryst Pharmaceuticals Rating Lowered to Neutral at Zacks

2013-02-08 05:07:24| Biotech - Topix.net

They currently have a $2.00 price target on the stock. A number of other analysts have also recently weighed in on BCRX.

Tags: rating neutral lowered pharmaceuticals

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
25.11adidas BECKENBAUER
25.11KISS DVD
25.1116
25.113
25.11HiHi Jets DVD CRUSH THE FRONTLINE
25.11SnowMan I DO ME
25.11m.u
25.11ICLS5& 2022
More »